[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"influenza-vaccine-response\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:influenza-vaccine-response":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100606581","phase-4-characterizing-the-human-airway-immune-response-to-flumist-vaccination-100606581",false,"NCT07177417","Characterizing the Human Airway Immune Response to FluMist Vaccination","EVax-3: Human Upper and Lower Airway Mucosal Immune Response to FluMist Vaccination","EVax-3","Inclusion Criteria:\n\n* Healthy adults aged 18-40 years\n* Able to understand and give written informed consent\n* In stable health, as determined by medical history and targeted physical exam related to the history\n\nExclusion Criteria:\n\n* Prisoners\n* Anyone unable to provide full written informed consent\n* Pregnant women and nursing mothers or women who are planning to become pregnant during the study interval\n* Female subjects who are sexually active with male partners who are not actively on hormonal contraception or who do not have an IUD in place\n* Vaccination with a seasonal influenza vaccine or documented infection with seasonal influenza in the past 9 months\n* Receipt of any vaccine in the 28 days prior to the pre-vaccination study visit or planned receipt of any non-study vaccine before completion of study day 28 visit\n* Current smokers\n* BMI \\> 40\n* Individuals with an immunocompromising medical condition or who have received systemic immunosuppressants or immune-modifying drugs for \\> 14 days in total within 6 months prior to screening (for corticosteroids ≥ 10 mg\u002Fday of prednisone equivalent for \\> 14 days total) or is anticipating the need for immunosuppressive treatment at any time during participation in the study\n* Individuals who currently have symptomatic acute or unstable chronic disease requiring medical or surgical care, to include significant change in therapy or hospitalization, at the discretion of the investigator\n* History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the study\n* Have donated blood, blood products, or bone marrow within 30 days before study entry, plan to donate blood at any time during the duration of study participation, or plan to donate blood within 30 days after the last blood draw.\n* Current ongoing participation in a clinical trial evaluating an investigational agent unless the trial is in follow up only and the last dose of the investigational agent was taken \\>30 days or \\>5 half-lives prior to enrollment, whichever is greater.\n* Any condition in the opinion of the investigator that would interfere with the proper conduct of the trial.\n\nFor participants willing to undergo bronchoscopy:\n\n* Any known chronic pulmonary, cardiovascular, neurologic or hematologic disorder that could, in the opinion of the physician bronchoscopist or the principal investigator, put the subject at unnecessary risk from the sedation and bronchoscopy procedures. These conditions may include, but are not limited to, the following: asthma, COPD, obstructive sleep apnea, pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, heart failure, previous myocardial infarction, hypertrophic cardiomyopathy, supraventricular tachycardia, paraplegia, quadriplegia, epilepsy, sickle cell disease, hemophilia, chronic anemia or active cancer.\n* Coagulopathy (primary or iatrogenic) which would contraindicate bronchoscopy for participants willing to have those procedures done. Any participant with an INR\\>1.4, PTT\\>40 or platelet count \\\u003C100,000 at study screening will not be eligible for bronchoscopy.\n* Evidence of significant pulmonary disease on the day of bronchoscopy, including pulse oximetry with oxygen saturation of 92% or less on room air, or infiltrate or pleural effusion on an upright PA and lateral chest x-ray performed on the day of bronchoscopy.\n* Allergy or contraindication to anesthesia for participants willing to have bronchoscopy done.",true,"ALL","18 Years","40 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","The goal of this clinical trial is to measure the immune response in the blood, nose, and lungs after participants receive either the FDA-approved inactivated influenza vaccine or the FDA-approved intranasal FluMist vaccine. The study will evaluate immune responses in groups of healthy, non-pregnant, volunteers between the ages of 18 and 40. The main purpose of the study is to measure the change in influenza vaccine-specific antibodies in the lower lungs and nose between vaccination and 14 days after participants receive the vaccine. All participants will be randomized to receive one of the two seasonal flu vaccines and will have blood and back of the nose swabs collected throughout the study. Some study participants will choose to undergo optional bronchoscopy procedures and will be included in the part of the study looking at lower lung immune responses.",[29,30,31],"Healthy Young Adults","Influenza Vaccines","Influenza Vaccine Response",[33,34,35,36,37,38],"FluMist","bronchoscopy","bronchoalveolar lavage","endobronchial biopsy","nasopharyngeal swab","inactivated influenza vaccine","RECRUITING","2025-09-09",{"date":42,"type":43},"2025-09-17","ACTUAL",{"date":40,"type":43},{"date":46,"type":23},"2028-11",{"name":48,"class":49},"Washington University School of Medicine","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":24,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":50},"100579713","effect-of-oral-supplements-for-influenza-vaccine-response-100579713","NCT06827873","Effect of Oral Supplements for Influenza Vaccine Response","Effect of Oral Supplement Intervention on Influenza Vaccine Efficacy: a Randomized Controlled Clinical Trial","EOSIIVE-RCT","Inclusion Criteria:\n\n1. Age 60-70 years old\n2. Body Mass Index (BMI) 18.5-26.9 kg\u002Fm²\n3. No influenza vaccination in the past year\n4. Able to understand and sign the informed consent form, and capable of completing the full follow-up process\n\nExclusion Criteria:\n\n1. Severe lipid metabolism disorders\n2. Use of lipid-lowering medications, weight loss drugs, or insulin within the past three months\n3. Vaccination with other vaccines within the past three months\n4. Use of probiotics or prebiotics within the past three months\n5. Use of steroids, immunosuppressants, or other hormonal medications within the past year\n6. Immunodeficiency diseases\n7. Severe vaccine allergy history\n8. Liver or kidney metabolic disorders\n9. Occurrence of fever, common cold, severe diarrhea, or other diseases within the past month\n10. Poorly controlled chronic diseases (such as blood pressure, blood sugar)\n11. Intake of influenza antiviral drugs within the past two weeks\n12. Cognitive function impairment\n13. Planning to undergo surgery in the near future","60 Years","70 Years",{"count":62,"type":23},45,[64],"NA","The aim of this clinical trial is to explore the efficacy of fatty acid and bile acid based supplements on enhancing influenza vaccine immune response in adults aged 60-70 years. The objectives of this study are:\n\n1. To explore the efficacy of fatty acid and bile acid based supplements on enhancing flu vaccine immune response.\n2. To evaluate the safety of fatty acid and bile acid use in elders.\n3. To explore the potential role of microbiota in regulating immune response.\n\nThis study will conduct a randomized clinical trial to compare the efficacy of fatty acid \u002F bile acid (Tauro Ursodesoxy Cholic Acid, TUDCA)supplements on enhancing vaccine immune response. The antibody's titer and safety indicators after influenza vaccination will be evaluated. Study process are:\n\n1. Participants will be required to intake the assigned supplement or placebo daily for 25 days;\n2. Receive a influenza vaccine on day 4;\n3. Provide blood samples three times and stool samples twice at base line and endpoint respectively;\n4. The antibody's titer and safety indicators will be analyzed and compared among groups.\n\nThis study aims to establish a theoretical foundation for utilizing nutritional strategies to enhance vaccine-induced immune responses and to provide a scientific framework for developing oral vaccine boosters.",[31],[68,69,70,71,72],"Vaccine Efficacy","Elderly Immunity","Fatty Acid Supplementation","Gut Microbiota","Randomized Controlled Trial","NOT_YET_RECRUITING","2025-02-10",{"date":76,"type":43},"2025-02-14",{"date":78,"type":23},"2025-02",{"date":80,"type":23},"2025-10",{"name":82,"class":49},"Tsinghua University"]